Multiparametric MRI for prostate cancer: Seeing is believing


  • Christopher A. Warlick MD, PhD

    Corresponding author
    1. Department of Urology, University of Minnesota, Minneapolis, Minnesota
    • Corresponding author: Christopher Warlick, MD, PhD, 420 Delaware Street SE, Mayo Mail Code 394, Minneapolis, Minneapolis, MN 55455; Fax: (612) 626-0428;

    Search for more papers by this author

  • See referenced original article on pages 2876–82, this issue.


Salami and colleagues present an evaluation of multiparametric magnetic resonance imaging (MRI) combined with MRI/ultrasound fusion prostate biopsies compared with the Prostate Cancer Prevention Trial High-Grade nomogram to predict the presence of clinically significant disease in a largely referral-based population of men. Their report echoes a growing chorus of studies suggesting the ability of MRI and image-guided biopsies to improve the identification of men with clinically significant disease.